Upregulation of the long noncoding RNA GJA9-MYCBP and PVT1 is a potential diagnostic biomarker for acute lymphoblastic leukemia

IF 1.5 Q4 ONCOLOGY

Cancer reports Pub Date : 2024-07-12 DOI:10.1002/cnr2.2115

Kamal Shahamiri, Arash Alghasi, Najmaldin Saki, Hossein Teimori, Gholam Abbas Kaydani, Setare sheikhi

{"title":"Upregulation of the long noncoding RNA GJA9-MYCBP and PVT1 is a potential diagnostic biomarker for acute lymphoblastic leukemia","authors":"Kamal Shahamiri, Arash Alghasi, Najmaldin Saki, Hossein Teimori, Gholam Abbas Kaydani, Setare sheikhi","doi":"10.1002/cnr2.2115","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Acute lymphoblastic leukemia (ALL) is the most common type of blood cancer in children. Aberrant expression of long noncoding RNAs (lncRNAs) may set stages for ALL development. LncRNAs are emerging as a novel diagnostic and prognostic biomarker for ALL. Herein, we aimed to evaluate the expression of lncRNA GJA9-MYCBP and PVT1 in blood samples of ALL and healthy individuals.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>As a case–control study, 40 pairs of ALL and healthy individual samples were used. The expression of <i>MYC</i> and each candidate lncRNA was measured using quantitative real-time PCR. Any possible association between the expression of putative noncoding RNAs and clinicopathological characteristics was also evaluated.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>LncRNA GJA9-MYCBP and PVT1 were significantly upregulated in ALL samples compared with healthy ones. Similarly, mRNA levels of MYC were increased in ALL samples than control ones. Receiver operating characteristic curve analysis indicated a satisfactory diagnostic efficacy (<i>p</i>-value <.0001), suggesting that lncRNA GJA9-MYCBP and PVT1 may serve as a diagnostic biomarker for ALL. Linear regression analysis unveiled positive correlations between the expression level of MYC and lncRNA GJA9-MYCBP and PVT1 in ALL patients (<i>p</i>-values <.01).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>In this study, we provided approval for the clinical diagnostic significance of lncRNA GJA9-MYCBP and PVT1that their upregulations may be a diagnostic biomarker for ALL.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11240143/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.2115","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Acute lymphoblastic leukemia (ALL) is the most common type of blood cancer in children. Aberrant expression of long noncoding RNAs (lncRNAs) may set stages for ALL development. LncRNAs are emerging as a novel diagnostic and prognostic biomarker for ALL. Herein, we aimed to evaluate the expression of lncRNA GJA9-MYCBP and PVT1 in blood samples of ALL and healthy individuals.

Methods

As a case–control study, 40 pairs of ALL and healthy individual samples were used. The expression of MYC and each candidate lncRNA was measured using quantitative real-time PCR. Any possible association between the expression of putative noncoding RNAs and clinicopathological characteristics was also evaluated.

Results

LncRNA GJA9-MYCBP and PVT1 were significantly upregulated in ALL samples compared with healthy ones. Similarly, mRNA levels of MYC were increased in ALL samples than control ones. Receiver operating characteristic curve analysis indicated a satisfactory diagnostic efficacy (p-value <.0001), suggesting that lncRNA GJA9-MYCBP and PVT1 may serve as a diagnostic biomarker for ALL. Linear regression analysis unveiled positive correlations between the expression level of MYC and lncRNA GJA9-MYCBP and PVT1 in ALL patients (p-values <.01).

Conclusions

In this study, we provided approval for the clinical diagnostic significance of lncRNA GJA9-MYCBP and PVT1that their upregulations may be a diagnostic biomarker for ALL.

Abstract Image

查看原文本刊更多论文

长非编码 RNA GJA9-MYCBP 和 PVT1 的上调是急性淋巴细胞白血病的潜在诊断生物标志物。

背景：急性淋巴细胞白血病（ALL急性淋巴细胞白血病（ALL）是最常见的儿童血癌。长非编码 RNA（lncRNA）的异常表达可能为急性淋巴细胞白血病的发展埋下隐患。LncRNAs 正在成为一种新型的 ALL 诊断和预后生物标志物。在此，我们旨在评估LncRNA GJA9-MYCBP和PVT1在ALL和健康人血液样本中的表达：方法：作为一项病例对照研究，我们使用了 40 对 ALL 和健康个体样本。方法：作为病例对照研究，使用了40对ALL和健康个体样本，使用定量实时PCR技术测量了MYC和每个候选lncRNA的表达。研究还评估了推测的非编码RNA的表达与临床病理特征之间可能存在的关联：结果：与健康样本相比，LncRNA GJA9-MYCBP和PVT1在ALL样本中明显上调。同样，ALL样本中MYC的mRNA水平也高于对照样本。接收者操作特征曲线分析表明诊断效果令人满意（P值结论）：在这项研究中，我们证实了 lncRNA GJA9-MYCBP 和 PVT1 的临床诊断意义，即它们的上调可能是 ALL 的诊断生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer reports Medicine-Oncology

CiteScore

2.70

自引率

5.90%

发文量

160

审稿时长

17 weeks